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Autologous adult stem cells (ASCs) are increasingly being administered to patients with 
limited evidence from clinical trials that they are safe and effective. The marketing of 
autologous ASCs predominantly over the Internet by companies based in low-to-middle 
income countries, such as the Bahamas, Mexico, India and China, is well documented.(1, 2) 
However, even in countries such as the United States, Japan, and Australia, physicians are 
prescribing autologous ASCs to patients outside the context of clinical trials. These doctors 
often form part of loose collaborative networks of clinicians, businesses, patients and 
researchers operating both domestically and across national boundaries. The emergence of 
these networks not only puts patients who seek out these interventions at risk: it threatens 
to undermine the very basis of ‘good medical practice’. 
Bionetworks 
The concept of bionetworks has been described in a study, funded by the Ethics & Social 
Science Research Council in the UK, which traces the relationships between physicians, 
science entrepreneurs, researchers, patients and healthcare providers that are offering ASCs 
outside clinical trials as ‘experimental therapies’ across Asia.(3) According to the authors, 
bionetworks operate mostly, although not exclusively, within the private healthcare sector, 
and work to exploit differences and similarities in the provision of healthcare, standards of 
evidence, and regulatory infrastructure across geographical contexts.(4) They may also work 
to shape healthcare policies and regulations across international borders.  
One example of how global bionetworks may influence health-related policies recently 
emerged in the US following reports that Texas Governor Rick Perry had received a 
preparation of expanded autologous adipose-derived mesenchymal stem cells for back pain 
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in 2012. This procedure was administered by Houston orthopaedic surgeon, Dr. Stanley 
Jones, who himself had received a similar one for arthritic pain at a clinic in Japan that, at 
the time, was in a partnership with a South Korean-based company, RNL Bio – a company 
that has been previously been investigated following the deaths of two South Korean 
patients who had travelled to China and Japan for administration of autologous ASCs. Jones 
has since co-founded a company called Celltex Therapeutics, which secured an exclusive 
license in 2012 to market RNL Bio’s cell processing technology from its American subsidiary. 
At the same time, the Texas Medical Board, whose members are appointed by the 
Governor, determined that the “use of investigational agents constitutes the practice of 
medicine” and adopted the Standards for Use of Investigational Agents, which allows 
physicians to use stem cells in certain clinical settings pending approval from an IRB.  
This approach – which has yet to be replicated in other states – has been the subject of 
extensive criticism, principally because it appears to substitute formal regulatory oversight 
with IRB approval,(5) although the FDA has issued Celltex with a warning letter for non-
compliance to federal manufacturing standards, which supersede state laws. The Texas case 
does, however, highlight a number of issues that have both domestic and international 
salience. These include the ways in which regulatory approaches to biomedical products 
may be translated across national borders, the impact that bionetworks are having in 
shaping global healthcare and challenging the sometimes uncertain distinction between 
clinical trials and ‘innovative medicine’, and the failure of regulators worldwide to 
adequately monitor and control the emergence and translation of cellular therapies. 
Examination of the regulatory context in Japan, the United Kingdom, and Australia make 
clear the difficulties in regulating these practices. 
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In Japan, which has a large domestic market for novel cell-based therapeutics, licensed 
practitioners and institutions are allowed to administer autologous ASCs under a regulatory 
framework that is very similar to that advanced in Texas. While manufacturers must seek 
approval from the Pharmaceuticals and Medical Devices Agency to market products, in a 
manner broadly similar to how the FDA approves biological drugs in the US, practitioners in 
Japan may also prescribe unapproved medicines outside the context of clinical trials. This 
act is considered to fall within the scope of ‘physician discretion’ in medical practice, and is 
permitted under the Medical Practitioner’s Law (1948). In addition, the Ministry of Health, 
Labour and Welfare has issued the Practice Notice: Regarding the Practice of Regenerative 
and Cell Therapy with Autologous Cells and Tissue in Medical Institutions (2010), which only 
requires medical institutions intending to implement medicines using autologous stem cells 
or tissues to seek approval from an institutional ethics committee.   
Many practitioners, clinics and bio-companies have taken advantage of this situation. Media 
outlets in Japan have reported that more than 20 clinics are offering unproven interventions 
with autologous ASCs outside clinical trials, which may increase once the government 
implements proposed changes to fast-track cell products through the regulatory approval 
process.(6) The situation is similar in Australia, where the manufacturing and therapeutic 
use of autologous cells is excluded from regulation under the Therapeutic Goods (Excluded 
Goods) Order of the Therapeutic Goods Act (1989). This exclusion means that ASCs can be 
administered to consenting patients by any registered medical practitioner without any 
form of external review. As a consequence, like Japan, the number of private clinics offering 
autologous ASCs has increased, with many being run by practitioners who are not specialists 
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in the management of the medical conditions experienced by the patients who seek their 
care.(7) 
In contrast, the United Kingdom has been relatively successful in controlling the use of 
autologous cellular therapies. Even though practitioners may access unapproved medicinal 
products through the manufacturer’s ‘specials’ licence program and the ‘hospital use’ 
exemption scheme, the administration of autologous ASCs outside the standard of care 
appears to have been restricted to use within clinical trials. This situation may, at least in 
part, have been influenced by actions taken by the British General Medical Council against 
Dr Robert Trossel, who was struck off the medical registry in 2010 for unjustifiably 
administering inappropriate stem cell-based interventions to patients affected by multiple 
sclerosis.(8) Although in this case, Trossel was administering an allogeneic preparation 
(found to also contain bovine neural cells) at a clinic in Rotterdam, it is likely that his 
deregistration would have sounded a stern warning to other British practitioners 
considering offering unproven interventions with any stem cell-based product outside 
clinical trials.  
Regulatory Challenges 
The socio-political and regulatory contexts that enable the exploitation of cell therapies in 
some countries and not others are, of course, highly complex. The issues in play not only 
relate to the confounding of research and clinical practice, they reflect ongoing 
contestations over the standards of evidence that should be required before novel 
interventions are introduced into clinical settings. They also raise profound questions 
concerning professionalism, patient vulnerability, and professional and personal autonomy.  
Lysaght et al. (2013). American Journal of Bioethics. 126(11): 941-943. 
 
One of the greatest challenges in regulating autologous cell products will thus be finding a 
balance between protecting vulnerable patient populations while still allowing enough 
flexibility in the regulations for doctors to develop new and innovative cell-based therapies. 
There also needs to be recognition, that due to small market sizes, autologous cell-based 
therapies are unlikely to provide a viable business model if forced to follow the established 
drug pathway for all indications, particularly where regulators operate on a cost-recovery 
basis.(9) Repositioning the applicable frameworks to provide more flexible cost-effective 
pathways to market whilst establishing product safety and efficacy may be a better 
alternative than simply exempting entire classes of therapeutics from regulation. 
Professional medical bodies should also play a greater role in providing guidance that aligns 
doctors with international standards of clinical care and research ethics and, where 
necessary, enforce appropriate sanctions for breaches of unethical or unprofessional 
conduct. For these practices, whether conducted independently or as part of a bionetwork, 
are not only detrimental to the emerging field of stem cell medicine, they potentially 
undermine public trust in the medical profession and the agencies that regulate it.  
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